Catalyst Wire Dossier Catalyst Wire Dossier

XL888

Drug timelines are a Plus or Pro feature.

2 regulatory and trial events tracked for XL888, covering 2015-08-21 to 2026-03-02. Get the full timeline:

Most recent: Clinical Trial Update: XL888 + Vemurafenib + Cobimetinib for Unresectable BRAF Mutated Stage III/IV Melanoma [Phase 1]

See pricing